Sheila is the co-founder and former Chief Executive Officer of Gossamer Bio, Inc. She serves as the Chair of the Board of Directors of ADARx Pharmaceuticals, Inc. and as a Director at Janux Therapeutics, Inc. She previously served as Chair of the Board of Directors of Turning Point Therapeutics, Inc. and on the Board of Directors at Five Prime Therapeutics, Inc. (acquired by Amgen Inc.) and Ambrx, Inc. (acquired by a consortium of investors).

Prior to Gossamer Bio, Sheila served as Chief Medical Officer of Receptos, Inc. (acquired by Celgene Corp.). At Receptos, she built the development, regulatory and quality organizations and advanced the pipeline of drug candidates, including Zeposia®, which is approved for multiple sclerosis and for ulcerative colitis.

Prior to Receptos, Sheila was Vice President of the Global Clinical Development Group in Immunology at Bristol-Myers Squibb (BMS), where she led clinical development and supported numerous global regulatory filings and approvals for Orencia® and Nulojix®. She was also an immunoscience franchise leader with strategic oversight over the BMS immunology clinical and discovery pipeline and business development activities. Prior to BMS, Sheila held roles in the immunology, tissue growth and repair clinical development groups at Genentech, Inc. where she worked on Ocrevus®, Rituxan®, Xolair®, and a number of other programs across all stages of development and served as the Avastin® franchise team leader.

Earlier in her career, she was a management consultant in McKinsey & Company’s healthcare practice. Sheila received both her MD in the accelerated Honors Program in Medical Education and her BS in Biomedical Engineering with highest distinction from Northwestern University. She completed her internal medicine internship and residency at Brigham and Women’s Hospital and Harvard Medical School and additional fellowship training in allergy/immunology at UCSF and Stanford.